Molecular Therapy for Non-small Cell Lung Cancer

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 661

Special Issue Editor


E-Mail Website
Guest Editor
Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA
Interests: biomarker; onco-immunology; lung cancer; precision oncology

Special Issue Information

Dear Colleagues,

The field of lung cancer has undergone transformative progress in recent years, especially in our molecular comprehension of non-small-cell lung cancer (NSCLC). Innovative techniques in genomic profiling, liquid biopsies, and onco-immunotherapy catalyze a paradigm shift, from a historically uniform approach to a nuanced, patient-centric model of care. "Molecular Therapy for Non-Small-Cell Lung Cancer," a Special Issue guest-edited by Dr. Weijie Ma, aims to compile cutting-edge research articles and reviews that shed light on the molecular underpinnings of NSCLC and explore clinically relevant targeted therapies. This Special Issue has a broad scope, encompassing well-established molecular targets like EGFR, ALK, BRAF, ROS1, RET, HER-2, and PD-L1, as well as emerging markers and pathways at the forefront of oncological research. Additionally, we aim to tackle the challenges associated with acquired resistance, managing side effects, and incorporating molecular therapies into traditional treatment regimens. Contributions that delve into the role of pathological evaluations, including the utility of tissue- and blood-based biomarkers for therapy optimization and response monitoring, are particularly encouraged.

We invite interdisciplinary submissions from molecular biology, pathology, pharmacology, and clinical oncology to create a comprehensive repository of the latest insights and perspectives. The ultimate goal is to enrich our collective understanding, facilitate improvements in patient outcomes, and provide direction for future investigations in this dynamic field.

Dr. Weijie Ma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small-cell lung cancer
  • molecular targets
  • tyrosine kinase inhibitors (TKIs)
  • immune checkpoint inhibitors (ICIs)
  • biomarker
  • oncogenic driver mutation
  • acquired resistance
  • precision oncology
  • lung cancer
  • next generation sequence

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop